Table 3 Clinical and laboratory data among homozygous carriers of P2 allele versus heterozygous group and non-carriers
From: Interleukin-4 gene intron 3 VNTR polymorphism in adult acute myeloid leukemia
Variables | P1P1 and P1P2 (n = 26) | P2P2 (n = 34) | P value |
|---|---|---|---|
Age (years), Mean ± SD | 37.1 ± 11.50 | 47.6 ± 14.70 | 0.004 |
Sex, n (%) | 0.909 | ||
Male | 18 (69.2) | 24 (70.6) | |
Female | 8 (30.8) | 10 (29.4) | |
Extramedullary involvement, n (%) | 0.700 | ||
Positive | 12 (46.2) | 14 (41.2) | |
Negative | 14 (53.8) | 20 (58.8) | |
TLC (× 103/µL), Median (IQR) | 12.6 (4.5–30) | 28 (15–130) | 0.025 |
Hemoglobin (g/dL), | 0.120 | ||
Mean ± SD | 7.82 ± 2.21 | 7.2 ± 2.1 | |
Platelets (× 103/µL), × 109/L), Median (IQR) | 66 (18 -141) | 19 (13–62) | 0.010 |
PB blasts (%) | 0.005 | ||
Median (IQR) | 20 (2–49) | 58 (33–69) | |
BM blasts (%),Median (IQR) | 60 (38–80) | 80 (67–85) | 0.023 |
FAB Subtype, n (%) | 0.973 | ||
M0, M1 | 6 (23.1%) | 8 (23.5%) | |
M2 | 14 (53.8%) | 19 (55.9%) | |
M4/5, M6, M7 | 6 (23.1%) | 7 (20.6%) | |
Immunophenotyping, n (%) | |||
HLA-DR | 22 (84.6) | 31 (91.2) | 0.432 |
CD34 | 21 (80.8) | 28 (82.4) | 0.874 |
MPOX | 20 (76.9) | 30 (88.2) | 0.244 |
Cytogenetic risk groups, n (%)* | 0.32 | ||
Favorable | 4 (19) | 3 (10) | |
Intermediate and poor | 16 (61.53) | 27 (90) | |
Complete remission | 23 (88.55) | 22 (64.7%) | 0.035 |